NDRAU has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NDRAU has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Debt-to-EBITDA measures a company's ability to pay off its debt.
ENDRA Life Sciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.18 Mil. ENDRA Life Sciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.15 Mil. ENDRA Life Sciences's annualized EBITDA for the quarter that ended in Mar. 2024 was $-10.90 Mil. ENDRA Life Sciences's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was -0.03.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's
The historical rank and industry rank for ENDRA Life Sciences's Debt-to-EBITDA or its related term are showing as below:
During the past 10 years, the highest Debt-to-EBITDA Ratio of ENDRA Life Sciences was -0.03. The lowest was -0.55. And the median was -0.06.
The historical data trend for ENDRA Life Sciences's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ENDRA Life Sciences Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Debt-to-EBITDA | Get a 7-Day Free Trial | -0.07 | -0.06 | -0.06 | -0.04 | -0.04 |
ENDRA Life Sciences Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Debt-to-EBITDA | Get a 7-Day Free Trial | -0.04 | -0.04 | -0.04 | -0.07 | -0.03 |
For the Diagnostics & Research subindustry, ENDRA Life Sciences's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Diagnostics & Research industry and Healthcare sector, ENDRA Life Sciences's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where ENDRA Life Sciences's Debt-to-EBITDA falls into.
Debt-to-EBITDA measures a company's ability to pay off its debt.
ENDRA Life Sciences's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as
Debt-to-EBITDA | = | Total Debt | / | EBITDA | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | EBITDA | |
= | (0.202 | + | 0.192) | / | -10.245 | |
= | -0.04 |
ENDRA Life Sciences's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as
Debt-to-EBITDA | = | Total Debt | / | EBITDA | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | EBITDA | |
= | (0.178 | + | 0.146) | / | -10.9 | |
= | -0.03 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.
ENDRA Life Sciences (NAS:NDRAU) Debt-to-EBITDA Explanation
In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.
Be Aware
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's
Thank you for viewing the detailed overview of ENDRA Life Sciences's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Renaud Bertrand Maloberti | officer: Chief Commercial Officer | 10 ACORN WAY, GEORGETOWN MA 01833 |
Anthony Digiandomenico | director | 3600 GREEN COURT, SUITE 350, ANN ARBOR MI 48105 |
Michael Milos Thornton | officer: Chief Technology Officer | 3600 GREEN COURT, SUITE 350, ANN ARBOR MI 48105 |
David R. Wells | officer: Chief Financial Officer | 2801 OCEAN PARK BLVD., SUITE 339, SANTA MONICA CA 90405 |
Francois Roger Michelon | director, officer: Chief Executive Officer | 430 N. JUNO LANE, JUNO BEACH FL 33406 |
Michael Harsh | director | 3600 GREEN COURT, SUITE 350, ANN ARBOR MI 48105 |
Lou Basenese | director | 3600 GREEN COURT, SUITE 350, ANN ARBOR MI 48105 |
Alexander Y Tokman | director | C/O MICROVISION, INC., 6222 185TH AVENUE NE, REDMOND WA 98052 |
Sanjiv Sam Gambhir | director | 3600 GREEN COURT, SUITE 350, ANN ARBOR MI 48105 |
Longboard Capital Advisors, Llc | 10 percent owner | 9665 WILSHIRE BLVD., SUITE 430, BEVERLY HILLS CA 90212 |
Brett Conrad | 10 percent owner | 1312 CEDAR ST., SANTA MONICA CA 90405 |
From GuruFocus
By Business Wire Business Wire • 06-07-2023
By Business Wire Business Wire • 12-05-2022
By Business Wire • 08-30-2023
By Business Wire Business Wire • 06-08-2022
By Business Wire • 11-06-2023
By Business Wire Business Wire • 08-01-2022
By Business Wire Business Wire • 05-25-2022
By Business Wire • 07-06-2023
By Business Wire • 08-14-2023
By Business Wire Business Wire • 05-02-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.